Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Glucagon is used for the treatment of hypoglycemia, and glucagon receptor antagonists are under development for the treatment of type 2 diabetes. Moreover, glucagon-like peptide (GLP)-1 and GLP-2 receptor agonists appear to be promising therapies for the treatment of type 2 diabetes and intestinal disorders, respectively. This review discusses the physiological, pharmacological, and therapeutic actions of the proglucagon-derived peptides, with an emphasis on clinical relevance of the peptides for the treatment of human disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Glucagon and regulation of glucose metabolism
Jiang, G., & Zhang, B. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2002 · Cited by 905
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
Self-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Self-citationScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Self-citationElliott, R. M., Morgan, L. M., Tredger, J. A., Deacon, S., Wright, J., & Marks, V. (1993) · Journal of Endocrinology · doi:10.1677/joe.0.1380159 · Cited by 695
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
Herrmann, C., Göke, R., Richter, G., Fehmann, H.-C., Arnold, R., & Göke, B. (2009) · Digestion · doi:10.1159/000201231 · Cited by 597
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Self-citationAhrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435
Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427
Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421 · cited 1×
“HbA1c levels in short-term studies in type 2 diabetics (1, 3).”
BackgroundButeau, J., Roduit, R., Susini, S., & Prentki, M. (1999) · Diabetologia · doi:10.1007/s001250051238 · Cited by 413 · cited 1×
“GLP-1 increases cell proliferation, phosphoinositide 3kinase, and PDX-1 in islet cell lines in a PKC- and epidermal growth factor receptor-dependent manner (22, 23, 24, 122).”
BackgroundDiverse causes of hypoglycemia-associated autonomic failure in diabetes.
Cryer, P. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmra031354 · Cited by 411 · cited 1×
“of normal glucagon secretion for counterregulation during insulin-induced hypoglycemia (31, 32), and susceptible individuals with type 1 diabetes may use glucagon as an adjunctive therapy for the treatment of severe hypoglycemia.”
BackgroundBaggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372 · cited 1×
“The anorectic actions of oxyntomodulin are detectable in the absence of functional glucagon receptors but are absent in GLP-1 receptor (GLP-1R) –/– mice, further suggesting that oxyntomodulin regulates food intake through the GLP-1R (6).”
BackgroundSelf-citationShah, P., Vella, A., Basu, A., Basu, R., Schwenk, W. F., & Rizza, R. A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6993 · Cited by 368
Edwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344
Modulation of specific intestinal epithelial progenitors by enteric neurons
Bjerknes, M., & Cheng, H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211278098 · Cited by 325
Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Holz, G. G., Leech, C. A., & Habener, J. F. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.30.17749 · Cited by 188
Stress impairs murine intestinal barrier function: improvement by glucagon-like peptide-2
Cameron, H. L., & Perdue, M. H. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085373 · Cited by 128 · cited 1×
“GLP-2 enhances mucosal barrier function by both transcellular and paracellular pathways (11), and these actions are maintained in the setting of experimental intestinal inflammation or exogenous stress (25, 26).”
Background
Research works printed but not linked: 101
- 10.1016/S0014-2999(00)00600-2 · DOI · Paper page
- 10.1053/jpsu.2000.6861 · DOI
- 10.1097/00006676-200005000-00003 · DOI · Paper page
- 10.2337/diabetes.53.9.2492 · DOI · Paper page
- 10.1016/0167-0115(88)90099-7 · DOI
- 10.1007/s001250051445 · DOI · Paper page
- 10.1152/ajpendo.1994.266.3.E459 · DOI · Paper page
- 10.1136/gut.47.1.112 · DOI · Paper page
- 10.2337/diabetes.54.1.146 · DOI · Paper page
- 10.1152/ajpendo.1999.277.5.E937 · DOI · Paper page
- 10.1007/BF00400461 · DOI
- 10.1210/endo.138.11.5482 · doi:10.1210/endo.138.11.5482 · Paper page
- 10.1152/ajpendo.1997.272.6.E1050 · DOI · Paper page
- 10.1210/en.2004-1119 · DOI
- 10.1152/ajpgi.2000.279.6.G1249 · DOI · Paper page
- 10.2337/diabetes.52.1.124 · DOI · Paper page
- 10.2337/diabetes.50.10.2237 · DOI · Paper page
- 10.1152/ajpgi.00231.2002 · DOI · Paper page
- 10.1210/endo.134.5.8156917 · doi:10.1210/endo.134.5.8156917 · Paper page
- 10.1152/ajpgi.1996.271.3.G477 · DOI · Paper page
- 10.1210/jc.2003-030421 · DOI · Paper page
- 10.1053/gast.1997.v112.pm9178688 · DOI
- 10.1210/endo.142.10.8430 · DOI · Paper page
- 10.2337/diabetes.52.2.365 · DOI · Paper page
- 10.2337/diab.44.9.1126 · DOI · Paper page
- DhanvantariS, Seidah NG, and Brubaker PL. Role of prohormone convertases in the tissue-specific processing of proglucagon.Mol Endocrinol10: 342–355, 1996. · doi:10.1210/mend.10.4.8721980 · Paper page
- 10.1210/me.2002-0306 · DOI · Paper page
- 10.1073/pnas.93.15.7911 · DOI · Paper page
- 10.1038/nbt0797-673 · DOI · Paper page
- 10.1152/ajpgi.1999.276.1.G79 · DOI · Paper page
- 10.1055/s-2004-826159 · DOI · Paper page
- 10.1016/S0303-7207(98)00096-3 · DOI · Paper page
- 10.1210/en.2004-1389 · DOI
- 10.1210/endo.130.1.1309325 · doi:10.1210/endo.130.1.1309325 · Paper page
- FurutaM, Yano H, Zhou A, Rouille Y, Holst JJ, Carroll R, Ravazolla M, Orci L, Furuta H, and Steiner DF. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2.Proc Natl Acad Sci USA94: 6646–6651, 1999. · DOI · Paper page
- 10.1073/pnas.0237106100 · DOI · Paper page
- 10.1074/jbc.M209165200 · DOI · Paper page
- 10.1210/en.2003-0007 · DOI · Paper page
- 10.1016/S0016-5085(03)00667-X · DOI · Paper page
- 10.1080/003655202317316006 · DOI
- 10.1152/ajpendo.00197.2004 · DOI · Paper page
- 10.1016/0196-9781(95)00078-X · DOI
- 10.2337/diacare.27.8.1915 · DOI · Paper page
- HartmannB, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB, and Holst JJ. In vivo and in vitro degradation of glucagon-like peptide-2 in humans.J Clin Endocrinol Metab85: 2884–2888, 2000. · DOI · Paper page
- 10.1016/0014-5793(85)80879-6 · DOI
- 10.1210/endo-115-1-102 · DOI
- 10.1126/science.8384375 · DOI · Paper page
- 10.1053/gast.2001.22555 · DOI · Paper page
- 10.1126/science.6278587 · DOI · Paper page
- 10.1111/j.1469-7793.2001.0375c.xd · DOI · Paper page
- 10.1074/jbc.M108378200 · DOI · Paper page
- 10.2337/diabetes.52.3.751 · DOI · Paper page
- 10.1523/JNEUROSCI.22-23-10470.2002 · DOI · Paper page
- 10.1038/297156a0 · DOI
- 10.1210/me.2004-0196 · DOI
- 10.1210/jc.2002-021545 · DOI · Paper page
- 10.2337/diabetes.51.3.691 · DOI · Paper page
- 10.2337/diabetes.53.2.410 · DOI · Paper page
- 10.1007/s004280000374 · DOI
- 10.2337/diacare.27.6.1335 · DOI · Paper page
- 10.1073/pnas.120069197 · DOI · Paper page
- 10.1124/pr.55.1.6 · DOI · Paper page
- 10.1016/0167-0115(93)90435-B · DOI · Paper page
- 10.1073/pnas.96.4.1569 · DOI · Paper page
- 10.1007/BF02934484 · DOI
- 10.1006/bbrc.2001.4999 · DOI
- 10.1016/0026-0495(95)90288-0 · DOI
- 10.1016/j.regpep.2004.07.009 · DOI · Paper page
- 10.1210/endo-119-4-1467 · DOI · Paper page
- 10.1210/endo-123-4-2009 · DOI · Paper page
- 10.2337/diab.47.8.1253 · DOI · Paper page
- 10.1007/s001250100006 · DOI · Paper page
- 10.1053/jpsu.2001.22284 · doi:10.1053/jpsu.2001.22284
- 10.1016/S0022-3468(00)90040-X · DOI
- 10.2337/diabetes.53.12.3267 · DOI · Paper page
- 10.1210/endo.140.4.6643 · doi:10.1210/endo.140.4.6643 · Paper page
- 10.1074/jbc.270.17.10136 · DOI · Paper page
- 10.1073/pnas.91.8.3242 · DOI · Paper page
- 10.1139/y90-239 · DOI · Paper page
- 10.1007/BF01538078 · DOI
- 10.1111/j.1365-2362.1988.tb01046.x · DOI · Paper page
- 10.1152/ajpgi.1998.275.5.G911 · DOI · Paper page
- 10.1080/003655201750422648 · DOI
- 10.1053/j.gastro.2005.02.033 · DOI
- 10.1210/endo.137.11.8895391 · DOI · Paper page
- 10.2337/diabetes.49.7.1156 · DOI · Paper page
- 10.1172/JCI20911 · doi:10.1172/jci20911 · Paper page
- 10.1016/0303-7207(94)90162-7 · DOI
- 10.1006/jsre.2000.5917 · DOI
- 10.1152/ajpendo.2000.278.1.E134 · DOI · Paper page
- 10.2337/diab.42.11.1678 · DOI · Paper page
- 10.1016/S0167-0115(01)00316-0 · DOI
- 10.1007/s00125-005-1692-8 · DOI
- 10.1080/00365529850171486 · DOI · Paper page
- 10.1016/S0016-5085(99)70555-X · DOI · Paper page
- YewKH, Hembree M, Prasadan K, Preuett B, McFall C, Benjes C, Crowley A, Sharp S, Tulachan S, Mehta S, Tei E, and Gittes G. Crosstalk between BMP and TGF-beta signaling is essential for exendin-4 induced insulin-positive differentiation of AR42J cells.J Biol Chem. In press.
- 10.1074/jbc.M005510200 · DOI
- 10.1074/jbc.M201358200 · DOI
- 10.1053/gast.2000.16489 · DOI · Paper page
- 10.1074/jbc.274.43.30459 · DOI · Paper page
- 10.2337/diabetes.48.12.2358 · DOI · Paper page
Cited by
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Roopchand, D. E., Carmody, R. N., Kuhn, P., Moskal, K., Rojas-Silva, P., Turnbaugh, P. J., & Raskin, I. (2015) · Diabetes · doi:10.2337/db14-1916 · Cited by 678
Everard, A., & Cani, P. D. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9288-6 · Cited by 261
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Amato, A., Cinci, L., Rotondo, A., Serio, R., Faussone-pellegrini, M. S., Vannucchi, M. G., & Mulè, F. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01476.x · Cited by 124
Metadata
- Authors
- Sinclair, E. M., & Drucker, D. J.
- Venue
- Physiology
- Publisher
- American Physiological Society
- Published
- 2005-10
- Volume
- 20
- Issue
- 5
- Pages
- 357-365
- ISSN
- 0886-1714 (ISSN-L)
- 1548-9213
- 1548-9221
- OpenAlex
- W2088954563
- Cited by
- 87
- References
- 28
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.